Our Pipeline

---

Our first drug product (ORX-102) is being developed for Diffuse Intrinsic Pontine Glioma (DIPG), a glioblastoma-like tumor in the brain stem and one of the most resistant of all cancers.  ORX-102 qualifies as an Orphan Drug Product for the treatment of intractable, high-grade gliomas in the brain. We further plan to conduct a clinical trial with ORX-102 in patient with recurrent medulloblastoma who have DIPG-like characteristics. Despite the success of current therapies, medulloblastoma patients who survive live with major disabilities caused by those therapies.

Upon completion of our initial clinical trials, we plan to conduct a clinical trial with ORX-102 for the treatment of glioblastoma multiforme (GBM). GBM is difficult to treat with drug therapy and is associated with poor patient survival.  Over 90% of patients with astrocytoma have high-grade glioblastoma multiforme tumors when initially diagnosed; and these patients have a median survival of about 1 year from diagnosis with standard-of-care surgery, and radiation therapy with Temodar®. The five-year survival rate for patients with GBM and associated regional metastases using currently available therapies is less than 3%.